COPAXONE® stands the test of time as a multiple sclerosis therapy

COPAXONE® has been proven effective in 3 “Class I” clinical trials1-3, which are studies that meet the highest standards of the American Academy of Neurology.4 In combination, these studies showed that COPAXONE® effectively reduced relapses and new lesions as measured by magnetic resonance imaging (MRI).1-3

The COPAXONE® 2-year pivotal trial

Committing to a relapsing-remitting multiple sclerosis (RRMS) therapy like COPAXONE® can help you effectively manage your MS. In fact, the pivotal (2-year) trial for COPAXONE® demonstrated proven effectiveness.1 This “Class I” trial formed the foundation of the Food and Drug Administration’s (FDA) approval of COPAXONE®—introducing a new class of RRMS therapy thought to work in a unique way. Learn more about how this trial was designed in the study backgrounder.

Reducing relapses over the long term

Results from this 2-year “Class I” trial showed that COPAXONE® effectively reduces relapses by 29% in people with RRMS.1 Fewer relapses may mean more time to do the things you enjoy!

Extending the benefits—the COPAXONE® extension study

After the 2-year pivotal trial was completed, 208 of the original 251 participants continued on in what is known as an “open-label” extension.5 Learn more about how the COPAXONE® extension study was designed in the study backgrounder. This study extension has now been going on for more than a decade—with a commitment to continue to 15 years.6,7 So, the effectiveness of COPAXONE® has been shown in the longest continuous, open-label, prospective study ever of people with RRMS.6

No other RRMS therapy has been studied in this way, for this long!6,7

10 years...and counting!

If you’re like many people with relapsing-remitting multiple sclerosis (RRMS), you are probably wondering where you’ll be in the future. As you may know, each case of MS is unique, and individual responses to MS therapy can vary.

But, the COPAXONE® pivotal trial and extension study demonstrate how COPAXONE® helped the 108 people with RRMS who stayed in the study over a 10-year period. Here are the results from this study after a decade of use:

People who remained in the study and took COPAXONE® MS therapy continuously for an average of 10 years had approximately 80% fewer relapses than they had before going into the study. That means they went from experiencing an average of approximately 1½ relapses a year to approximately 1 relapse every 5 years.6

Experts agree that COPAXONE® effectively reduces relapses and future damage for many people.1-3,6 And, the proven results for the 108 participants involved in the pivotal trial and open-label extension study further support the long-term benefits of COPAXONE®.1-3,6 Everyone’s experience may be different, so talk to your doctor to see if COPAXONE® may be right for you.

Next Topic:
Safety

077005212/070986